Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

NCT00043446 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.

Conditions

  • Ovarian Neoplasms

Interventions

DRUG

intravenous T900607-sodium

Sponsors & Collaborators

  • Tularik

    lead INDUSTRY

Principal Investigators

  • Kerrie Boyd · Tularik

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043446 on ClinicalTrials.gov